×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: MDS 2026 — PD Genetic and Molecular Mechanisms
mechanism
1,422 words
KG: MDS 2026 — PD Genetic and Molecular Mechanisms
2026-03-26
kind:mechanism
section:mechanisms
state:published
mds2026
parkinsons
genetics
lrrk2
gba
snca
Contents
MDS 2026 — PD Genetic and Molecular Mechanisms
⚙
Mechanism Info
Name
MDS 2026 — PD Genetic and Molecular Mechanisms
Summary
Comprehensive coverage of Parkinson's disease genetic and molecular mechanism research from MDS 2026 (Seoul, Oct 4-8): LRRK2, GBA, SNCA, emerging risk genes, and mechanistic pathways
Knowledge Graph
Related Hypotheses (19)
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Smartphone-Detected Motor Variability Correction
Score: 0.56
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
Chromatin Accessibility Restoration via BRD4 Modulation
Score: 0.56
Epigenetic Memory Erasure via TET2 Activation
Score: 0.52
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.47
Epigenetic Memory Reprogramming for Alzheimer's Disease
Score: 0.47
Arginine Methylation Enhancement Therapy
Score: 0.46
Programmable Neuronal Circuit Repair via Epigenetic CRISPR
Score: 0.42
Synthetic Biology Rewiring via Orthogonal Receptors
Score: 0.42
Temporal TET2-Mediated Hydroxymethylation Cycling
Score: 0.41
Partial Neuronal Reprogramming via Modified Yamanaka Cocktai
Score: 0.40
KDM6A-Mediated H3K27me3 Rejuvenation
Score: 0.38
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.38
DNMT1-Targeting Antisense Oligonucleotide Reset
Score: 0.36
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.44
Conditional CRISPR Kill Switches for Aberrant Protein Cleara
Score: 0.45
Show 14 more
Related Analyses (30)
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Show 25 more
Related Experiments (30)
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeuti
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
GLP-1 Agonist Responder Prediction Study — Precision Medicin
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper
clinical · proposed · Score: 0.40
Non-Motor Symptom Progression in Parkinson's Disease — Mecha
clinical · proposed · Score: 0.40
Parkinson's Disease Subtype Classification — Precision Medic
clinical · proposed · Score: 0.40
Peroxisome Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Prodromal Parkinson's Disease Biomarker Development — Early
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Sirtuin Pathway Dysfunction Validation in Parkinson's Diseas
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
ALS Therapeutic Landscape — Programs by Phase and Modal
disease · Pages share 3 hypotheses
Wnt/β-Catenin Signaling Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
WNK1-Bilirubin Signaling in Neuroinflammation and Neuro
mechanism · Pages share 3 hypotheses
vip-vasoactive-intestinal-peptide-signaling-neurodegene
mechanism · Pages share 3 hypotheses
VEGF Signaling and Cerebral Angiogenesis in Neurodegene
mechanism · Pages share 3 hypotheses
Vagus Nerve Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
Ubiquitin-Proteasome System Dysfunction in Neurodegener
mechanism · Pages share 3 hypotheses
ubiquitin-proteasome-dysfunction-neurodegeneration
mechanism · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Therapeutic Targets in Neurodegeneration
mechanism · Pages share 3 hypotheses
Tertiary Lymphoid Organs in Neurodegeneration
mechanism · Pages share 3 hypotheses
TBK1 Autophagy and Neuroinflammation ALS/FTD Causal Cha
mechanism · Pages share 3 hypotheses
Tau Seeding and Propagation Pathway
mechanism · Pages share 3 hypotheses
T-Cell Dysfunction in Neurodegeneration
mechanism · Pages share 3 hypotheses
Show 10 more